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Abstract Patients with multiple tumors, either synchronous or
metachronous, can have metastatic disease or suffer from mul-
tiple independent primary tumors. While proper diagnosis of
these patients is important for prognosis and treatment, this can
be challenging using only clinical and histological criteria. The
aim of the present study was to evaluate the value of mitochon-
drial D310 mutation analysis in diagnostic questions regarding
tumor clonality for awide range of tumor types. Sanger sequenc-
ing of D310 was performed on a diagnostic cohort of 382 pa-
tients with 857 tumors that were previously analyzed using rou-
tine molecular analysis on genomic DNA. The D310 mononu-
cleotide repeat was frequently somatically mutated (56/321,
17 %) in several tumor types, including breast, head and neck,
gynecological, lung, colorectal, and skin tumors. For 84/327
(26 %) patients, a D310 mutation was detected in at least one
of their tumors; for these patients, D310 can be used to deter-
mine the clonal relationship between their multiple tumors.
Clonality assessments based on mitochondrial DNA (mtDNA)
and routine genomic DNA analysis were concordant in 52/73
(71 %) patients. We conclude that D310 mutation status might
aid in determining clonality of clinically challenging synchro-
nous or metachronous tumors. To this end, next generation
sequencing targeted genomic DNA assays should be
complemented with mtDNA markers, such as the D310 repeat.
Keywords Mitochondrial DNA . Tumor clonality .
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Introduction
When a patient presents with multiple tumors, either synchro-
nous or metachronous, the question arises whether this is met-
astatic (recurrent) disease or, alternatively, the patient suffers
frommultiple primary tumors, as appears to be the case in 8 %
of cancer patients [1]. To distinguish between multiple inde-
pendent primary tumors and metastatic disease is of prime
importance for prognosis and treatment [2] but can be chal-
lenging, when only clinical and histological criteria are avail-
able. Since tumor cells differ from normal cells by the pres-
ence of clonal DNA aberrations, these can be used to deter-
mine whether or not a clonal relationship exists between mul-
tiple tumors within one patient [2–4].
Most molecular clonality assays focus on genomic DNA.
Human cells, however, also contain numerous copies of mi-
tochondrial DNA (mtDNA). Mutations in mtDNA initially
result in heteroplasmic cells (cells with mutant and non-
mutant mitochondrial DNA molecules). Upon cellular expan-
sion, these heteroplasmic cells can achieve mutant DNA
homoplasmy (all mtDNA molecules within one cell harbor
the same mutation), as has been demonstrated in tumor
models, human tumors, and tumor cell lines [5–8]. Apparent-
ly, homoplasmic mtDNA aberrations have been frequently
found in human tumors [9], notably in a polymorphic cytosine
mononucleotide repeat within the non-coding displacement-
loop (D-loop) region (D310) [10]. In several studies on differ-
ent tumor types, mitochondrial DNA alterations have been
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used as a marker for clonality [11–14]. The aim of the present
study was to evaluate for a wide range of tumor types whether
or not D310 mutation analysis helps to solve diagnostic ques-
tions regarding tumor clonality.
For this study, we selected patients with multiple synchro-
nous or metachronous tumors, for which the question of a
clonal relationship was raised leading to routine molecular
analysis on genomic DNA. We addressed the following ques-
tions: (1) Do these tumors have mtDNA D310 mutations? (2)
Are the tumors clonally related based on mtDNA analysis and
does this correspond to the clonality status assessed by routine
genomic DNA analysis?
Materials and methods
We studied a cohort of patients with synchronous or
metachronous tumors for which routine molecular clonality
analysis on genomic DNA had been performed between Jan-
uary 2006 and April 2013 at the Erasmus Medical Center,
Rotterdam, The Netherlands. All cases concerned patients
for which pathologists or clinicians had previously submitted
a request for molecular analysis in view of questions regarding
diagnosis, prognosis, and/or patient treatment. For routine
analysis, normal and tumor DNA had been extracted from
formalin-fixed paraffin-embedded (FFPE) tissue blocks using
proteinase K and, for extractions from 2009 onwards, 5 %
Chelex 100 resin, as previously described [15]. DNAwas used
in accordance with the Code of Proper Use established by the
Dutch Federation of Medical Scientific Societies (https://
www.federa.org/sites/default/files/digital_version_first_part_
code_of_conduct_in_uk_2011_12092012.pdf). On these
tumors, depending on the amount of tissue available and the
tumor type, different combinations of routine molecular
analyses had been performed, among which loss of
heterozygosity (LOH) analysis, TP53 mutation analysis fol-
lowing abnormal P53 immunohistochemical staining, and/or
mutation analysis for other genes.
Of 466 patients eligible for inclusion in the study, 63 were
excluded because no archival normal or tumor DNA was
available, 17 because the original report was unavailable,
and 4 because this was incomplete. In total, 857 tumors from
382 patients were included. Online Resource 1 shows an over-
view of all tumor details. Consecutive tumors in any single
patient included have been numbered T1 to T7, in chronolog-
ical order with T1 being the first diagnosed; in most cases this
was the primary tumor.
PCR amplification of D310 was performed with normal and
tumor DNA using Kapa 2G robust hotstart readymix (Kapa
Biosystems, Woburn, MA) and M13-tailed custom-made
primers (forward TGT AAA ACG ACG GCC AGT - TTG
AAT GTC TGC ACA GCC AC and reverse CAG GAA
ACA GCT ATG ACC - GGG GTT TGG CAG AGA TGT
G). After purification using Exonuclease I and FastAP
Thermosensitive Alkaline Phosphatase (Fermentas, Thermo
Fisher Scientific,Waltham,MA), PCR products were sequenced
with M13 primers using the BigDye Terminator v3.1 kit (Ap-
plied Biosystems, Foster City, CA). Fragments were detected on
a ABI 3730xl genetic analyzer (Applied Biosystems). D310
repeat length (nucleotide position 303–309) was evaluated by
visual inspection using Mutation Surveyor v.3.24 software
(SoftGenetics, State College, PA). An alteredD310 repeat length
in tumor DNA compared to patient-matched normal DNAwas
classified as a D310 mutation (either deletion or insertion). To
exclude genomic DNA amplification, DNA isolated from
mtDNA-less cells was used as a negative control (143B/206
ρ0, a kind gift of Dr. G.P. Comi, Dino Ferrari Centre, Neurosci-
ence Section, Department of Pathophysiology and Transplanta-
tion (DEPT), University of Milan, Milan, Italy).
Results
Detailed results on the analysis of D310 in 857 synchronous
or metachronous tumors of 382 patients are shown in Online
Resource 1. Corresponding normal DNA could be evaluated
in 332 patients and showedD310 repeat lengths of 6, 7, 8, or 9
cytosines (for 1, 187, 123, and 21 patients, respectively). Both
normal DNA and DNA from the first tumor (T1) could be
evaluated in 321 patients. A D310 mutation was found in
56/321 (17 %) of T1, of which 11/85 (13 %) in breast, 11/62
(18 %) in head and neck, 4/35 (11 %) in gynecological, 5/26
(19 %) in lung, 8/25 (32 %) in colorectal, and 3/19 (16 %) in
skin tumors (Fig. 1). In 35/56 (63%) tumors, an insertion of 1,
2, or 3 nucleotides was found (in 25, 7, and 3 tumors, respec-
tively); 21/56 (37 %) tumors showed a deletion of 1, 2, or
multiple nucleotides (18, 2, and 1 tumors, respectively).
Fig. 1 Percentage of D310 mutations in the chronologically first
diagnosed tumors of all patients. The tumors are categorized by tumor
type; after each tumor type, the number of tumors with an evaluable result
is shown between parentheses
596 Virchows Arch (2015) 467:595–602
T
ab
le
1
R
ou
tin
e
ge
no
m
ic
ve
rs
us
m
ito
ch
on
dr
ia
lD
N
A
re
su
lts
fo
r
84
pa
tie
nt
s
w
ith
a
D
31
0
m
ut
at
io
n
in
at
le
as
to
ne
of
th
ei
r
tu
m
or
s
G
en
om
ic
D
N
A
re
su
lts
M
ito
ch
on
dr
ia
lD
N
A
re
su
lts
Pt
T
1
T
2
T
3
T
4
T
5
T
P5
3
L
O
H
O
th
er
C
on
cl
us
io
n
N
T
1
T
2
T
3
T
4
T
5
C
on
cl
us
io
n
C
on
co
rd
an
t:
2
pr
im
ar
y
tu
m
or
s
9
L
ar
yn
x,
20
03
Pl
eu
ra
,2
00
6
Y
es
Y
es
T
1
≠T
2
7
7
9
T
1
≠T
2
22
L
un
g,
19
94
L
ar
yn
x,
20
06
Y
es
T
1
≠T
2
8
7
8
T
1
≠T
2
25
B
re
as
t,
20
03
B
re
as
t,
20
06
Y
es
Y
es
T
1
≠T
2
8
9
8
T
1
≠T
2
26
A
dn
ex
,2
00
6
K
id
ne
y,
20
06
Y
es
T
1
≠T
2
N
E
8
9
T
1
≠T
2
36
To
ns
il,
20
06
L
un
g,
20
07
Y
es
Y
es
T
1
≠T
2
8
7
8
T
1
≠T
2
51
To
ns
il,
20
07
E
so
ph
ag
us
,2
00
7
L
un
g,
20
07
Y
es
Y
es
(T
1
=
T
2)
≠T
3
8
8
8
9
(T
1
=
T
2)
≠T
3
63
C
er
vi
x,
20
06
C
ol
on
,2
00
7
L
iv
er
,2
00
7
Y
es
Y
es
T
1
≠T
3
&
T
2
≠T
3
8
8
8
10
(T
1
=
T
2)
≠T
3
64
L
un
g,
20
07
A
dr
en
al
gl
an
d,
20
07
Y
es
T
1
≠T
2
8
10
8
T
1
≠T
2
95
Ly
m
ph
no
de
,2
00
0
B
re
as
t,
20
08
Y
es
Y
es
T
1
≠T
2
8
7
8
T
1
≠T
2
11
8
Pr
os
ta
te
,2
00
2
Sk
in
,2
00
8
Y
es
T
1
≠T
2
7
7
8
T
1
≠T
2
15
2
B
re
as
t,
19
93
B
re
as
t,
20
09
Y
es
Y
es
T
1
≠T
2
8
7
8
T
1
≠T
2
15
5
B
re
as
t,
19
93
B
re
as
t,
20
09
Y
es
Y
es
T
1
≠T
2
9
9
8
T
1
≠T
2
16
3
To
ng
ue
,2
00
8
M
ax
ill
a,
20
09
Y
es
Y
es
T
1
≠T
2
7
7
9
T
1
≠T
2
18
5
C
ol
on
,2
00
6
C
ol
on
,2
01
0
Y
es
T
1
≠T
2
8
7
8
T
1
≠T
2
20
0
B
re
as
t,
20
10
Pe
ri
to
ne
um
,2
01
0
Y
es
T
1
≠T
2
8
8
7
T
1
≠T
2
21
1
R
ec
tu
m
,2
00
2
D
uo
de
nu
m
,2
01
0
Y
es
Y
es
T
1
≠T
2
8
9
10
T
1
≠T
2
21
3
L
ar
yn
x,
20
05
E
so
ph
ag
us
,2
01
0
Y
es
Y
es
T
1
≠T
2
8
8
7
T
1
≠T
2
21
6
B
re
as
t,
19
98
B
la
dd
er
,2
01
0
Y
es
Y
es
T
1
≠T
2
8
8
9
T
1
≠T
2
23
2
B
re
as
t,
20
01
B
re
as
t,
20
10
Y
es
Y
es
T
1
≠T
2
8
8
7
T
1
≠T
2
24
0
M
ou
th
,2
01
0
L
un
g,
20
10
Y
es
T
1
≠T
2
8
9
8
T
1
≠T
2
25
0
M
ou
th
,2
00
7
L
un
g,
20
11
Y
es
Y
es
T
1
≠T
2
9
9
8
T
1
≠T
2
26
3
A
bd
om
en
,1
99
9
Pe
lv
is
,2
01
1
Y
es
T
1
≠T
2
8
7
8
T
1
≠T
2
27
2
M
ou
th
,2
00
9
L
un
g,
20
11
Y
es
Y
es
T
1
≠T
2
8
9
8
T
1
≠T
2
31
4
Sk
in
,2
01
1
Sk
in
,2
01
1
Y
es
Y
es
T
1
≠T
2
N
E
9
8
T
1
≠T
2
31
5
V
ag
in
a,
20
11
L
iv
er
,2
01
1
B
re
as
t,
20
11
Y
es
Y
es
T
1
≠(
T
2
=
T
3)
8
8
9
9
T
1
≠(
T
2
=
T
3)
35
2
L
un
g,
20
12
L
un
g,
20
12
Y
es
Y
es
T
1
≠T
2
8
8
7
T
1
≠T
2
36
7
C
ol
on
,2
01
2
Ly
m
ph
no
de
,2
01
2
Y
es
T
1
≠T
2
9
10
7
T
1
≠T
2
36
8
L
un
g,
20
10
Pa
nc
re
as
,2
01
2
Y
es
Y
es
T
1
≠T
2
8
7
8
T
1
≠T
2
37
1
B
re
as
t,
20
08
O
va
ry
,2
01
1
L
iv
er
,2
01
2
L
iv
er
,2
01
2
Y
es
Y
es
T
1
≠(
T
2
=
T
3
=
T
4)
8
7
8
8
8
T
1
≠(
T
2
=
T
3
=
T
4)
37
3
B
re
as
t,
20
10
O
va
ry
,2
01
1
Y
es
T
1
≠T
2
8
9
8
T
1
≠T
2
38
2
M
ou
th
,2
01
2
E
so
ph
ag
us
,2
01
3
Y
es
T
1
≠T
2
7
10
6
T
1
≠T
2
C
on
co
rd
an
t:
cl
on
al
ly
re
la
te
d
tu
m
or
s
6
N
as
op
ha
ry
nx
,2
00
6
M
ax
ill
ar
y
si
nu
s,
20
06
Y
es
T
1
=
T
2
8
9
9
T
1
=
T
2
41
B
re
as
t,
20
02
L
iv
er
,2
00
7
Y
es
T
1
=
T
2
9
7
7
T
1
=
T
2
Virchows Arch (2015) 467:595–602 597
T
ab
le
1
(c
on
tin
ue
d)
G
en
om
ic
D
N
A
re
su
lts
M
ito
ch
on
dr
ia
lD
N
A
re
su
lts
Pt
T
1
T
2
T
3
T
4
T
5
T
P5
3
L
O
H
O
th
er
C
on
cl
us
io
n
N
T
1
T
2
T
3
T
4
T
5
C
on
cl
us
io
n
59
Sk
in
,1
99
6
L
un
g,
20
07
Y
es
Y
es
T
1
=
T
2
8
9
9
T
1
=
T
2
62
C
ol
on
,2
00
4
C
ol
on
,2
00
6
Y
es
T
1
=
T
2
9
8
8
T
1
=
T
2
93
L
iv
er
,2
00
6
L
iv
er
,2
00
8
Y
es
Y
es
T
1
=
T
2
8
7
7
T
1
=
T
2
13
7
To
ns
il,
20
08
N
as
al
ca
vi
ty
,2
00
9
Y
es
Y
es
T
1
=
T
2
8
7
7
T
1
=
T
2
14
3
Ly
m
ph
no
de
,2
00
8
E
pi
gl
ot
tis
,2
00
8
L
un
g,
20
09
Y
es
Y
es
T
1
=
T
2
=
T
3
8
7
7
N
E
T
1
=
T
2
17
7
E
so
ph
ag
us
,2
00
9
E
so
ph
ag
us
,2
00
9
Y
es
T
1
=
T
2
7
8
8
T
1
=
T
2
18
4
L
iv
er
,2
00
7
C
ol
on
,2
01
0
Y
es
Y
es
T
1
=
T
2
8
10
10
T
1
=
T
2
19
6
O
va
ry
,2
01
0
E
nd
om
et
ri
um
,2
01
0
Y
es
T
1
=
T
2
7
10
10
T
1
=
T
2
26
5
L
ar
yn
x,
20
10
L
un
g,
20
11
Y
es
T
1
=
T
2
8
10
10
T
1
=
T
2
27
0
Ly
m
ph
no
de
,2
01
1
Ly
m
ph
no
de
,2
01
1
Y
es
T
1
=
T
2
8
9
9
T
1
=
T
2
29
9
O
va
ry
,2
01
1
U
te
ru
s,
20
11
Y
es
T
1
=
T
2
8
7
7
T
1
=
T
2
32
6
C
ol
on
,2
00
6
L
un
g,
20
12
Y
es
T
1
=
T
2
8
9
9
T
1
=
T
2
34
4
Sc
ro
tu
m
,2
01
2
Pl
eu
ra
,2
01
2
Y
es
T
1
=
T
2
8
10
10
T
1
=
T
2
34
7
Sk
in
,2
00
9
L
un
g,
20
12
Y
es
T
1
=
T
2
8
9
9
T
1
=
T
2
36
2
B
re
as
t,
20
11
L
un
g,
20
12
Sk
in
,2
01
2
Y
es
T
1
=
T
2
=
T
3
8
10
10
10
T
1
=
T
2
=
T
3
36
5
B
re
as
t,
20
12
C
ol
on
,2
01
2
Y
es
T
1
=
T
2
8
D
el
D
el
T
1
=
T
2
36
6
C
ol
on
,2
01
0
L
un
g,
20
12
Y
es
T
1
=
T
2
8
9
9
T
1
=
T
2
37
9
C
ol
on
,2
01
2
B
la
dd
er
,2
01
3
Y
es
Y
es
T
1
=
T
2
8
7
7
T
1
=
T
2
38
0
B
re
as
t,
20
11
Sk
in
,2
01
3
Y
es
Y
es
T
1
=
T
2
7
8
8
T
1
=
T
2
M
ito
ch
on
dr
ia
lD
N
A
:2
pr
im
ar
y
tu
m
or
s;
ge
no
m
ic
D
N
A
:c
lo
na
lly
re
la
te
d
tu
m
or
s
3
Sk
in
,2
00
3
Sk
in
,2
00
3
Y
es
Y
es
T
1
=
T
2
7
7
8
T
1
≠T
2
12
B
re
as
t,
20
03
Pe
ri
to
ne
um
,2
00
4
Y
es
Y
es
T
1
=
T
2
N
E
8
9
T
1
≠T
2
10
4
L
un
g,
20
08
L
un
g,
20
08
L
iv
er
,2
00
8
Y
es
Y
es
T
1
=
T
2
=
T
3
8
8
9
8
(T
1
=
T
3)
≠T
2
13
9
L
un
g,
20
07
L
un
g,
20
09
Y
es
T
1
=
T
2
8
8
7
T
1
≠T
2
23
7
E
so
ph
ag
us
,2
01
0
E
so
ph
ag
us
,2
01
0
Y
es
T
1
=
T
2
8
9
8
T
1
≠T
2
24
5
C
ol
on
,2
00
8
L
un
g,
20
10
Y
es
Y
es
T
1
=
T
2
7
7
8
T
1
≠T
2
26
8
L
ar
yn
x,
20
10
L
un
g,
20
11
Y
es
Y
es
T
1
=
T
2
8
8
9
T
1
≠T
2
33
4
To
ns
il,
20
08
Ly
m
ph
no
de
,2
01
2
Y
es
T
1
=
T
2
8
9
8
T
1
≠T
2
35
0
L
ar
yn
x,
20
10
L
ar
yn
x,
20
10
L
un
g,
20
12
Y
es
Y
es
T
1
=
T
2
=
T
3
N
E
7
8
7
(T
1
=
T
3)
≠T
2
M
ito
ch
on
dr
ia
lD
N
A
:c
lo
na
lly
re
la
te
d
tu
m
or
s;
ge
no
m
ic
D
N
A
:2
pr
im
ar
y
tu
m
or
s
27
St
om
ac
h,
20
00
Pa
nc
re
as
,2
00
6
Y
es
Y
es
T
1
≠T
2
8
7
7
T
1
=
T
2
21
9
L
un
g,
20
07
Sm
al
li
nt
es
tin
e,
20
10
Sm
al
li
nt
es
tin
e,
20
10
Y
es
T
1
≠(
T
2
=
T
3)
9
10
10
10
T
1
=
T
2
=
T
3
24
8
B
re
as
t,
20
00
B
re
as
t,
20
10
Y
es
T
1
≠T
2
9
8
8
T
1
=
T
2
26
2
B
re
as
t,
20
03
B
re
as
t,
20
11
Y
es
T
1
≠T
2
9
8
8
T
1
=
T
2
27
5
Pa
nc
re
as
,2
00
3
L
iv
er
,2
01
1
Y
es
T
1
≠T
2
8
9
9
T
1
=
T
2
32
4
E
pi
gl
ot
tis
,2
01
1
L
un
g,
20
12
Y
es
T
1
≠T
2
8
9
9
T
1
=
T
2
598 Virchows Arch (2015) 467:595–602
T
ab
le
1
(c
on
tin
ue
d)
G
en
om
ic
D
N
A
re
su
lts
M
ito
ch
on
dr
ia
lD
N
A
re
su
lts
Pt
T
1
T
2
T
3
T
4
T
5
T
P5
3
L
O
H
O
th
er
C
on
cl
us
io
n
N
T
1
T
2
T
3
T
4
T
5
C
on
cl
us
io
n
34
6
Ly
m
ph
no
de
,2
01
1
Pa
la
tu
m
,2
01
2
Y
es
T
1
≠T
2
9
10
10
T
1
=
T
2
D
is
co
rd
an
t:
co
m
pl
ex
17
8
B
la
dd
er
,2
00
3
L
un
g,
20
04
Sm
al
li
nt
es
tin
e,
20
04
Y
es
Y
es
T
1
≠(
T
2
=
T
3)
8
8
8
7
(T
1
=
T
2)
≠T
3
18
7
O
ro
ph
ar
yn
x,
20
04
Sk
in
,2
00
6
L
un
g,
20
10
L
un
g,
20
10
Y
es
Y
es
Y
es
T
1
≠T
2
≠T
3
≠T
4
8
8
8
7
7
(T
1
=
T
2)
≠(
T
3
=
T
4)
30
6
Ph
ar
yn
x,
20
11
M
ou
th
,2
01
1
L
ar
yn
x,
20
11
L
un
g,
20
11
Y
es
Y
es
T
1
≠T
2
≠T
4
7
7
8
7
7
(T
1
=
T
3
=
T
4)
≠T
2
31
6
E
so
ph
ag
us
,1
99
9
E
so
ph
ag
us
,2
00
2
E
so
ph
ag
us
,2
01
1
Y
es
Y
es
T
2
≠T
3
N
E
7
6
6
T
1
≠(
T
2
=
T
3)
34
0
L
un
g,
19
90
B
la
dd
er
,2
00
7
B
re
as
t,
20
09
G
ro
in
,2
01
2
B
la
dd
er
,2
01
2
Y
es
(T
2
=
T
4
=
T
5)
≠T
3
8
10
8
8
8
9
T
1
≠(
T
2
=
T
3
=
T
4)
≠T
5
N
o
co
m
pa
ri
so
n
po
ss
ib
le
46
B
re
as
t,
19
89
B
re
as
t,
20
07
N
o
co
nc
lu
si
on
8
8
9
T
1
≠T
2
69
St
om
ac
h,
20
07
C
ol
on
,2
00
7
N
o
co
nc
lu
si
on
8
7
8
T
1
≠T
2
91
To
ns
il,
20
06
Sk
in
,2
00
8
Y
es
Y
es
T
1
=
T
2
(u
nc
er
ta
in
)
8
9
9
T
1
=
T
2
10
7
C
ol
on
,1
99
5
C
ol
on
,1
99
5
V
er
te
br
a,
20
08
N
o
co
nc
lu
si
on
8
9
9
8
(T
1
=
T
2)
≠T
3
12
1
T
ho
ra
x,
19
96
Sk
in
,1
99
8
B
re
as
t,
20
08
N
o
co
nc
lu
si
on
8
8
8
10
(T
1
=
T
2)
≠T
3
12
6
B
re
as
t,
20
00
Pe
ri
to
ne
um
,2
00
8
N
o
co
nc
lu
si
on
8
8
7
T
1
≠T
2
17
3
B
re
as
t,
20
09
B
re
as
t,
20
09
N
o
co
nc
lu
si
on
9
7
9
T
1
≠T
2
17
9
Sk
in
,2
00
8
B
re
as
t,
20
09
Y
es
Y
es
T
1
=
T
2
(u
nc
er
ta
in
)
8
9
8
T
1
≠T
2
24
6
E
so
ph
ag
us
,2
01
1
E
so
ph
ag
us
,2
01
1
N
o
co
nc
lu
si
on
7
10
7
T
1
≠T
2
25
9
O
va
ry
,2
01
1
E
nd
om
et
ri
um
,2
01
1
O
va
ry
,2
01
1
N
o
co
nc
lu
si
on
8
10
9
10
(T
1
=
T
3)
≠T
2
37
2
To
ng
ue
,2
01
2
Pl
eu
ra
lf
lu
id
,2
01
2
Y
es
T
1
=
T
2
(u
nc
er
ta
in
)
8
9
8
T
1
≠T
2
Pa
tie
nt
s
ar
e
ca
te
go
ri
ze
d
ac
co
rd
in
g
to
th
e
fi
na
lr
es
ul
ts
of
bo
th
ge
no
m
ic
an
d
m
ito
ch
on
dr
ia
lD
N
A
an
al
ys
es
.G
en
om
ic
D
N
A
re
su
lts
ar
e
ba
se
d
on
T
P5
3
m
ut
at
io
n
an
al
ys
is
,L
O
H
an
al
ys
is
,a
nd
/o
r
ot
he
r
an
al
ys
es
(“
Y
es
”
in
di
ca
te
s
th
at
th
e
pa
rt
ic
ul
ar
an
al
ys
is
co
nt
ri
bu
te
d
to
th
e
fi
na
lc
on
cl
us
io
n)
.D
et
ai
ls
ab
ou
tt
he
ge
no
m
ic
D
N
A
an
al
ys
is
ar
e
pr
ov
id
ed
in
O
nl
in
e
R
es
ou
rc
e
2.
M
ito
ch
on
dr
ia
lD
N
A
re
su
lts
sh
ow
th
e
D
31
0
re
pe
at
le
ng
th
fo
r
al
la
na
ly
ze
d
tu
m
or
s
D
el
de
le
tio
n,
N
E
no
n-
ev
al
ua
bl
e,
pt
pa
tie
nt
,T
1-
T5
tu
m
or
1-
5
Virchows Arch (2015) 467:595–602 599
600 Virchows Arch (2015) 467:595–602
Of the 327 patients for whom D310 status could be deter-
mined, 243 (74 %) showed tumors without D310 aberrations,
while in 84 (26 %) a D310 mutation was detected in one or
more tumors (Table 1). Of the 84 patients with a D310 mutat-
ed tumor, 29 (35%) had clonally related tumors and 55 (65%)
had multiple primary tumors based upon D310 mutation sta-
tus. For 73 of these 84 patients, a final clonality status assessed
by genomic DNA molecular clonality analysis was available,
and in 52 (71 %), mtDNA and genomic DNA results were
concordant (Figs. 2 and 3; Online Resource 2).
Discussion
We found that the D310 mononucleotide repeat in mtDNA is
somatically mutated in 13 % of breast tumors, 18 % of head
and neck tumors, 11 % of gynecological tumors, 19 % of lung
tumors, 32 % of colorectal tumors, and 16 % of skin tumors.
These results are in close agreement with previous studies in
which D310 mutations were found in 11–28 % of breast tu-
mors, 0–16 % of head and neck tumors, 3–26 % of ovarian
tumors, 0–13 % of lung tumors, and 8–36 % of colon tumors
[10].
The identified D310mutationswere (nearly) homoplasmic,
indicating that these mutations are present in the majority of
the neoplastic cells and as a consequence must have occurred
early during oncogenesis. Heteroplasmic D310 mutations
have been reported in normal cells, achieving homoplasmy
in tumor cells [6, 12]. This suggests that D310 mutation status
might provide an ideal marker for tumor clonality. We found
in 84/327 (26 %) patients with synchronous or metachronous
tumors, for which the question of a clonal relationship was
raised, a D310 mutation in at least one of the tumors. In such
cases, D310 mutation status can be used to determine the
possible clonal relationship between the tumors. In a large
majority of patients (71 %), clonality status assessed by
mtDNA analysis and routine genomic DNA analysis were
concordant.
Discordant results between clonality status assessed by
mtDNA and genomic DNA analysis were found in 21/73
(29 %) patients. Clonality assays on multiple tumors often
result in some markers with concordant results but also
markers with discordant results between the different tumors.
Close scrutiny of individual markers is then necessary to de-
cide whether the tumors are clonally related or not in view of
the notion that genomic DNA analysis generates a likelihood
that multiple tumors might be clonally related, but does not
provide a definitive result. For 11 of our patients with discor-
dant results, a highly likely diagnostic result was obtained
because the tumors had a mutation in common, had mutually
exclusive mutations, or the first tumor had a mutation that was
not found in consecutive tumor(s). For these patients, the dis-
cordant mtDNA result was probably incorrect. Possible expla-
nations are firstly that two primary tumors by chance may
have acquired identical D310 mutations, secondly that de
novo D310 mutations acquired during tumor progression re-
sult in clonally related tumors with different D310 mutations,
and thirdly that intercellular or intracellular heterogeneity
(heteroplasmy) in regard of D310 mutations is maintained
during tumor development. For five patients, a likely diagnos-
tic result was obtained because a mutation was only present in
a consecutive tumor or the tumors showed common or differ-
ent LOH status of five or more loci. For another five patients,
the diagnostic result was weak, based on common or different
LOH status of less than five loci. To reliably classify such
tumors as clonally related or not, more informative genomic
and/or mtDNA markers would be necessary.
Although D310 mutations are the most common
mtDNA mutations in human cancer, other mtDNA dele-
tions, insertions, and point mutations have been described
[9]. Recently, next generation sequencing assays for mi-
tochondrial DNA have become available [16]. The use of
such assays for clonality analysis would result in the de-
tection of more mutations and probably result in a higher
predictive value. However, approximately 1.8 point muta-
tions in somatic mtDNA have been found in only 60 % of
cancers [9], emphasizing the necessity to include analysis
of genomic DNA as well. Mitochondrial DNA markers
Fig. 2 Routine genomic DNA and mitochondrial DNA results for
patient 352, whom was diagnosed with synchronous tumors of the right
(T1) and the left lung (T2). a Both tumors were diagnosed as
adenocarcinomas with a bronchioloalveolar growth pattern; T1 shows
absence of P53 staining, whereas T2 shows clear nuclear P53 staining.
Scale bars represent 50 μm. b Routine genomic DNA analysis was
performed on DNA isolated from normal (N) and both tumor tissues
(T1 and T2). LOH analysis of marker D17S786 (TP53) showed loss of
the large allele in T1 and loss of the small allele in T2, indicated by
arrowheads. The horizontal axis indicates the size of the DNA
fragments in basepair; the vertical axis indicates signal intensity. c
Routine Sanger sequencing of TP53 showed a p.Gln52* mutation only
in T1, and a p.Ser127Tyr mutation only in T2, both indicated by
arrowheads. d Sanger sequencing of mitochondrial DNA marker D310
showed an 8-cytosine repeat in normal DNA, no aberrations in T1, and a
1-bp deletion in T2, as indicated by the arrowhead. The results of routine
genomicDNA andmitochondrial DNA analysis both indicate that T1 and
T2 represent two primary tumors. H&E hematoxylin and eosin stain
Fig. 3 Clonality status assessed bymitochondrial DNA (mtDNA) results
compared to routine genomic DNA results for 73 patients with a D310
mutation in one or more of their tumors
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might be helpful when only a small number of cells are
available, in view of the high number of mtDNA copies
per cell compared to genomic DNA.
This study also has some limitations. Even though mtDNA
is present in numerous copies per cell, facilitating amplifica-
tion and analysis of a minute number of cells, no or an am-
biguous D310 mutation analysis result was obtained for 55/
382 (14 %) patients. This was mostly due to an insufficient
amount of DNA. For 11/84 (13 %) patients with D310 muta-
tions, a final clonality status assessed by genomic DNA anal-
ysis was not available, and for these patients, we were unable
to compare mtDNAwith genomic DNA results.
We conclude that D310 mutation status might aid in
clonality determinations of clinically challenging synchro-
nous or metachronous tumors, but as a single assay, has lim-
ited predictive value. To further evaluate the potential contri-
bution of mtDNA markers to assessment of tumor clonality,
we propose to include in existing next generation sequencing
targeted genomic DNA assays mtDNA markers, such as the
D310 repeat.
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